Partnering

**Media** 

Careers

Contact



erview

ess Releases

rents & Presentations

orporate Governance

nancials & Filings

ock Information


estor FAQs

estment Inquiries

## **Investor Relations**



pyright West LLC. Minimum 15 minutes delayed.





## orporate Profile

adius is a science-driven fully integrated biopharmaceutical company that is committed to developing and mmercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, 'MLOS® (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of estmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational aloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for stential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive east cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive east cancer.

ress Releases			
ov 01, 2018			
adius Health Announces Third Qua	arter 2018 Operating Results and Fina	ancial Guidance for FY 2018 and FY 2019	
et 12, 2018			
adius Health to Announce Third Qu 18	uarter 2018 Financial Results, Host Co	onference Call and Live Webcast on November 1,	
ew all press releases »			
Events & Presentations			
Nov 1, 2018 at 8:00 AM EDT			
Q3 Radius Health Inc Earnings Co	onference Call		
Oct 3, 2018 at 11:00 AM EDT			
Leerink Partners Roundtable Seri	es: Rare Disease & Oncology		
View all events & presentations »			
Aboutus	Investors	Careers	
	Overview		
	Press Releases  Events & Presentations		

Pipeline
By Connected

R&D

Partnering

Stock Information

Investor FAQs

Investment Inquiries

Partnering

Media

Contact

## Terms of Use Privacy Policy

This site is intended for United States residents only.

© 2018 Radius Health, Inc. RADIUS and TYMLOS are registered trademarks of Radius Health, Inc.

All other trademarks are the property of their respective owners.